Persisting Transglutaminase 6 Antibodies in Neurological Gluten‐Related Disorders
TG6 testing can identify patients at risk of accelerated brain atrophy, poorer physical functioning, and worsened mental health. IgA TG6 should be used as a diagnostic and monitoring test for patients with relevant neurological presentations, while achieving negative serology with a strict gluten-free diet should be the goal. ANN NEUROL 2026;99:274-282.
Authors
- Kevin Teh (ORCID: https://orcid.org/0000-0003-2538-5157)
- Iain D. Croall (ORCID: https://orcid.org/0000-0002-0987-9440)
- Nigel Hoggard (ORCID: https://orcid.org/0000-0002-6447-7639)
- Marios Hadjivassiliou (ORCID: https://orcid.org/0000-0003-2542-8954)
- Nick Trott (ORCID: https://orcid.org/0000-0001-8872-8773)
- Alberto Biancardi (ORCID: https://orcid.org/0009-0000-2765-0773)
- David S. Sanders (ORCID: https://orcid.org/0000-0002-8881-461X)
Institutions
- Sheffield Teaching Hospitals NHS Foundation Trust (GB)
- University of Sheffield (GB)
Publication Details
- Journal
- Annals of Neurology
- Published
- 2025-08-25
- DOI
- https://doi.org/10.1002/ana.78020
- Citations
- 1
- Primary Topic
- Celiac Disease Research and Management
- Type
- article
- Field-Weighted Citation Impact
- 1.81
Funders
- Beyond Celiac
- National Institute for Health and Care Research
- Department of Health and Social Care
- Medical Research Council
- NIHR Sheffield Biomedical Research Centre